Compounds > miglustat
Page last updated: 2024-08-23

miglustat and Carcinoma, Hepatocellular

miglustat has been researched along with Carcinoma, Hepatocellular in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hughes, D1
Block, TM; Blumberg, BS; Dwek, RA; Foster, GR; Gerlich, WH; Lu, X; Platt, FM1

Other Studies

2 other study(ies) available for miglustat and Carcinoma, Hepatocellular

ArticleYear
Gaucher disease: hematologic and oncologic implications.
    Clinical advances in hematology & oncology : H&O, 2011, Volume: 9, Issue:10

    Topics: 1-Deoxynojirimycin; Carcinoma, Hepatocellular; Enzyme Inhibitors; Enzyme Replacement Therapy; Gaucher Disease; Glucosylceramidase; Glucosyltransferases; Humans; Liver; Multiple Myeloma; Risk Factors; Spleen; Splenectomy

2011
Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin.
    Proceedings of the National Academy of Sciences of the United States of America, 1994, Mar-15, Volume: 91, Issue:6

    Topics: 1-Deoxynojirimycin; Animals; Antiviral Agents; Blotting, Western; Carcinoma, Hepatocellular; Culture Media; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Rabbits; Transfection; Tumor Cells, Cultured; Virion; Virus Replication; Virus Shedding

1994